On March 5, 2025, Zhejiang CDMO Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Biossincerity Pharmaceutical, received the CEP certificate (Certificate of Suitability to Monograph of the European Pharmacopoeia) issued by European Directorate for the Quality of Medicines & HealthCare (EDQM). It is the first CEP certificate for APIs of CDMO Pharmaceutical.

CEP certificate (Certificate of Suitability to Monograph of European Pharmacopoeia), is a certification issued by EDQM that the quality of APIs conforms to the requirement of European Pharmacopoeia. This certificate is not only widely recognized by all EU member states, but also recognized by many countries that have signed bilateral agreements, such as Canada, Australia, and New Zealand. It is an important pass for domestic API companies to enter the international market.

In the future, the company will transform into a higher-end industrial chain, strengthen innovation-driven development, meet international registration requirements, enhance global competitiveness, promote technological upgrades, further accelerate the pace of international business expansion, and provide global customers with higher-quality products and services.

Zhejiang CDMO Pharmaceuticals Co., Ltd. is an open, cooperative, and inclusive platform enterprise that integrates APIs and drug products, provides customers with high-quality and efficient CDMO/CMO services, and realizes the integrated development of innovative research and development and large-scale production. The project covers the API platform, solid preparation platform, oral liquid preparation platform, injection platform, topical preparation platform, BFS eye drop platform, and BFS inhalation preparation platform. Based on the cultural concept of innovative technology and serving health, the company promotes the high-quality development of the biopharmaceutical industry.